CA-IKOTEK
29.9.2022 15:01:38 CEST | Business Wire | Press release
Ikotek, the leading IoT original design manufacturer (ODM) and electronics manufacturing service (EMS) provider, is announcing expansion of its executive management team with industry veterans and continue their aggressive growth plans for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005870/en/
Ikotek - Your Trusted IoT ODM Partner (Photo: Business Wire)
Headquartered in San Diego, USA, Ikotek offers a one-stop-shop for IoT solutions across design and development, hardware build, testing and verification, product validation, software development, manufacturing and certification delivering high quality products and services to reduce complexity, speed up time to market, eliminate risk and reduce costs. The company has already designed, manufactured and shipped millions of IoT devices since its inception.
Ikotek, the only US-based global ODM with a pure IoT focus, combines end-to-end design consultancy across program management, R&D, sourcing, testing and production at its own as well as third party manufacturing facilities to produce designs for our customers. With a wide variety IoT projects in progress, such as asset tracking, dash cameras, PDAs and handhelds, point of sale (POS) devices and hardware for smart grid and metering deployments, Ikotek’s core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT at scale.
Led by Chief Executive Officer, Joe Peterson, who has more than 27 years of diverse experience across cellular and IoT industries in the US and international, Ikotek has gathered a team of industry veterans to amplify its vision of becoming the world’s most trusted IoT ODM. Recent additions to the US-based executive management team include:
Bill Leunis, the Vice President of Finance, who brings extensive experience in finance, operations and general management in manufacturing and EMS organizations. Previously, he has headed Finance in divisions of large multi-national corporations ranging in size from 500 to 20,000 people. In addition, he has served as CFO of a company, leading all aspects from its acquisition to IPO for eight years after going public.
Tim Newberg, the Vice President of Sales for the US and Canada, has joined with more than 25 years of experience and leadership in the wireless, broadband, consumer electronics and massive IoT industries. From hardware and software strategy to product marketing, sales and business development he has held senior executive positions at companies including Texas Instruments, Broadcom, Sequans, Rootmetrics, Polte and Sercomm.
Steve Burrington, the Head of North America Engineering, is a 25-year veteran of large and medium-sized wireless product development teams. Previously he served as Vice President of Engineering at CalAmp for the company’s telematics products. He has extensive experience of getting a diverse range of products to market, via organic development and JDM partnerships. In addition, he has held Vice President of Engineering roles at Netgear and Sierra Wireless.
These additions to the Ikotek management team have been supported by hires across the business and Ikotek now has more than 350 dedicated R&D employees and continues to add employees on a weekly basis.
“We’ve seen an incredible uptake of new customers over the last year and we’re excited to bring our unique ODM capabilities and advantages to customers,” said Peterson. “Supporting our customers with quick time-to-market, leading IoT industry expertise and cost-effective services and solutions is critical during a time where digital transformation is growing across all industries. To help manage growth, commercial excellence and new customers, I’m thrilled to welcome these three leading IoT and ODM capacities to our management team. We aim to serve our customers with local experts in North America and Europe and APAC so we can ensure that Ikotek is close to our customers and has local understanding of their needs.”
Ikotek targets mid-market IoT customers in response to increased demand for the design and build of products. The company’s ethos is to give customers a competitive advantage, through cost reductions and enable substantial savings to be achieved on their device design, manufacturing and certification costs. In addition, Ikotek is focused on taking customers’ projects from idea to market in record breaking time. In less than three months, Ikotek has provided end-to-end ODM services that took a complex IoT device to market including design, development and manufacturing.
“Ikotek exists to turn our customers’ device dreams into IoT reality,” Peterson added, pointing out the ways in which the company can help are listed on www.ikotek.com. “We’re keen to become customers’ indispensable partner in taking their innovations from concept to high volume product launches across global markets.”
About Ikotek
Ikotek is The IoT ODM. With a wide variety IoT projects currently underway, our core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT. We cover technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
